The Experts below are selected from a list of 8769 Experts worldwide ranked by ideXlab platform

Raimo Tuuminen - One of the best experts on this subject based on the ideXlab platform.

  • systemic use of calcium channel blockers associated with less increase in Central Retinal Thickness after uncomplicated cataract surgery
    Acta Ophthalmologica, 2019
    Co-Authors: Reeta Danni, Claudia Taipale, E Holmstrom, Lotta Ilveskoski, Raimo Tuuminen
    Abstract:

    PURPOSE To examine the role of systemic medication on the risk of pseudophakic cystoid macular edema (PCME) following uneventful cataract surgery. METHODS A total of 269 eyes undergoing routine cataract surgery. Spectral-domain optical coherence tomography imaging was conducted before surgery and at 28 days. Information about medication of the participants was gathered from The National Archive of Health Information (Kanta), an electronic pharmaceutical database. RESULTS Systemic medication with angiotensin converting enzyme inhibitor/angiotensin II receptor antagonists (p < 0.001), beta-blockers (β-blockers) (p = 0.002), calcium channel blockers (CCBs) (p < 0.001), nitrates (p =0.021) and lipophilic HMG-CoA reductase inhibitors (statins) (p < 0.001) were more frequently prescribed to diabetic compared with nondiabetic patients. In eyes with steroid monotherapy (N = 135), concomitant systemic medication with β-blockers (12.9 ± 24.0 μm versus 28.6 ± 59.5 μm, p = 0.045), CCBs (12.0 ± 22.1 μm versus 26.3 ± 55.6 μm, p = 0.041) and statins (12.9 ± 22.8 μm versus 30.0 ± 61.9 μm, p = 0.038) attenuated a change in Central Retinal Thickness (CRT) when compared to patients not receiving medication. In multivariable analysis, the use of CCBs remained as an independent protective factor against macular swelling at 28 days (-0.23; 95% CI [-0.43 to -0.04]; p = 0.021), when all systemic medications showing statistical significance were included (i.e. β-blockers, CCBs and statins) together with diabetes status. In eyes with nonsteroidal anti-inflammatory drug (NSAID) monotherapy (N = 67) and steroid and NSAID combination therapy (N = 67), CRT increase was moderate both with and without use of systemic medications. CONCLUSION Systemic vasoactive medication may be protective against CRT change induced by cataract surgery in eyes at risk of PCME such as those with postoperative steroid monotherapy.

  • poor glycemic control as a risk factor for pseudophakic cystoid macular edema in patients with diabetes
    Journal of Cataract and Refractive Surgery, 2017
    Co-Authors: Petteri Ylinen, Ilkka Laine, Juhamatti Lindholm, Raimo Tuuminen
    Abstract:

    Purpose To specify the risk factors for pseudophakic cystoid macular edema (CME) in patients with diabetes. Setting Kymenlaakso Central Hospital, Unit of Ophthalmology, Kotka, Finland. Design Prospective case series. Methods Patients with type 1 or type 2 diabetes having routine cataract surgery were evaluated. Spectral-domain optical coherence tomography imaging was performed before surgery and 1 month postoperatively. Results The study comprised 93 patients (95 eyes). The Central Retinal Thickness increase was 9.7 μm ± 1.7 (SEM) in diabetic patients with no retinopathy, 22.7 ± 8.6 μm in those who had nonproliferative retinopathy, and 73.8 ± 37.4 μm in those who had proliferative retinopathy (P  Conclusions Young patient age and poor glycemic control were risk factors for postoperative Central Retinal Thickness increase. This study showed it is necessary to identify, effectively treat, and follow-up with patients with diabetes who are at a greater risk for pseudophakic CME.

Takashi Ueta - One of the best experts on this subject based on the ideXlab platform.

  • long term increase in subfoveal choroidal Thickness after surgery for senile cataracts
    American Journal of Ophthalmology, 2014
    Co-Authors: Yasuo Noda, Taku Toyama, Asako Ogawa, Takashi Ueta
    Abstract:

    Purpose To evaluate the impact of cataract surgery on subfoveal choroidal Thickness and Central Retinal Thickness in the elderly. Design Prospective observational case series. Methods This cohort study included 29 eyes of 29 patients with senile cataract, but no previous ocular surgery or other ocular abnormality. All 29 eyes received standard surgery by phacoemulsification and intraocular lens implantation. Subfoveal choroidal Thickness and Central Retinal Thickness were measured at baseline and 1, 3, and 6 months postoperatively by spectral-domain optical coherence tomography. Multiple regression analysis was conducted to identify predictors of larger changes in subfoveal choroidal Thickness, including sex, age, baseline choroidal Thickness, axial length, refractive status before surgery, and duration of surgery. Results The 29 patients with senile cataract received cataract surgery without complication. Mean subfoveal choroidal Thickness was 193.8, 208.9, 210.2, and 209.3 μm at baseline and at postoperative 1, 3, and 6 months, respectively, with a statistically significant increase after surgery (repeated-measures ANOVA; P P  = .014) and thicker baseline choroid ( P  = .0048) predicted larger increases in subfoveal choroidal Thickness. In contrast, the tendency of transient increase in Central Retinal Thickness was not statistically significant. Conclusion Most elderly patients with senile cataracts are expected to maintain increased subfoveal choroidal Thickness for at least 6 months after cataract surgery.

Tg Lee - One of the best experts on this subject based on the ideXlab platform.

  • Evaluation of Central Retinal Thickness and subfoveal choroidal Thickness in normal eyes
    Acta Ophthalmologica, 2013
    Co-Authors: Dw Lee, J Kim, Cg Kim, Tg Lee
    Abstract:

    Purpose To determine Central Retinal Thickness and subfoveal choroidal Thickness using optical coherence tomography (OCT) and to evaluate association between both Thickness and age, gender and axial length. Methods Spectral domain OCT images (Bioptigen, Bioptigen, inc., Durham, NC) were obtained in 151 eyes of 151 healthy volunteers without Retinal diseases. The IOL master (Carl Zeiss Meditech) was used to measure the eye length to compensate axial scale factor of the SD-OCT images. The choroidal Thickness at the fovea and Central Retinal Thickness was measured. Statistical analysis using paired t-test and Pearson correlation were performed to evaluate the correlation between both Thickness and age, axial length, and gender. Results The mean and median age of the 151 subjects were 33.3 and 29 years old, respectively (range, 7 to 80 years). There were 57 males and 94 females. The mean and median axial lengths of the eye were 24.54±0.98 mm and 24.37 mm respectively. The mean Central Retinal Thickness were 213.89±14.64μm. Increasing age and axial length were not correlated with Central Retinal Thickness. The mean choroidal Thickness in these normal eyes was 214.43±13.63μm. Increasing age (Pearsun correlation - 0.193, R2=-0.0372, p=0.018) and increasing axial length (Pearsun correlation - 0.189, R2=-0.0359, p=0.020) were correlated with decreasing choroidal Thickness. Central Retinal Thickness and subfoveal choroidal Thickness have no relationship between them in our study (Pearsun correlation - 0.139, R2=0.0192, p=0.090 ). Conclusion Only the choroidal Thickness at the fovea in normal eyes showed an inverse correlation with age and axial length. And there is no significant relationship between Central Retinal Thickness and subfoveal choroidal Thickness.

Sascha Fauser - One of the best experts on this subject based on the ideXlab platform.

  • Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2011
    Co-Authors: Philipp Sebastian Muether, Manuel M. Hermann, Konrad Koch, Sascha Fauser
    Abstract:

    Background Complicated approval procedures and limited short-term surgical capacities can result in time delays between the definition of a medical indication for ranibizumab treatment in active neovascular age-related macular degeneration (AMD) and the starting of treatment. This study aimed to evaluate changes in visual acuity and Central Retinal Thickness over time, and their consequences for the patients concerned. Methods Sixty-nine patients indicated for first-time ranibizumab treatment and 21 patients with necessary re-treatment were included in the study. Visual acuity and spectral domain optical coherence tomography (SD-OCT) Central Retinal Thickness at the time of the indication examination were compared to values at the first-time treatment and during recurrent ranibizumab treatment. Results For first-time treatment, the delay between indication and treatment was significantly higher for patients with vision loss compared to those without vision loss (31.6 ± 20.5 vs. 24.0 ± 8.3 days, p  = 0.012). The increase in OCT Central Retinal Thickness was 50.4 ± 92.8 μm for patients with vision loss compared to 5.1 ± 63.4 μm for those without vision loss, p  = 0.029. A 1.1 logMAR line difference in vision loss was significant at p  = 0.01 for patients with a delay in treatment of less than or equal to 28 days (48/69 patients, 69.7%) compared to those with a delay of more than 28 days (21/69 patients, 30.3%). Conclusions Even though average visual decay was slow at about one logMAR line over 110 days, individual patients (8.7%) experienced rapid loss of one or more lines within 21 days. Administrative procedures should therefore be expedited so that delays do not exceed 2 weeks for the sake of vision preservation in individual patients.

  • delay between medical indication to anti vegf treatment in age related macular degeneration can result in a loss of visual acuity
    Graefes Archive for Clinical and Experimental Ophthalmology, 2011
    Co-Authors: Philipp Sebastian Muether, Manuel M. Hermann, Konrad R Koch, Sascha Fauser
    Abstract:

    Background Complicated approval procedures and limited short-term surgical capacities can result in time delays between the definition of a medical indication for ranibizumab treatment in active neovascular age-related macular degeneration (AMD) and the starting of treatment. This study aimed to evaluate changes in visual acuity and Central Retinal Thickness over time, and their consequences for the patients concerned.

Ramin Khoramnia - One of the best experts on this subject based on the ideXlab platform.

  • Injectable 0.19-mg fluocinolone acetonide intravitreal implant for the treatment of non-infectious uveitic macular edema
    Journal of Ophthalmic Inflammation and Infection, 2019
    Co-Authors: Lea F. Weber, Stefanie Marx, Gerd U. Auffarth, Alexander F. Scheuerle, Tamer Tandogan, Christian Mayer, Ramin Khoramnia
    Abstract:

    Background A retrospective observational clinical study to evaluate the safety and effectiveness of the injectable 0.19-mg fluocinolone acetonide intravitreal implant (ILUVIEN) in the treatment of non-infectious uveitic macular edema. Results Data are presented from eight patients (11 eyes) with non-infectious uveitic macular edema who were treated with a 0.19-mg fluocinolone acetonide implant. Nine out of 11 eyes were pseudophakic prior to implantation of fluocinolone acetonide implant, and both phakic eyes required cataract surgery during the follow-up period (the median follow-up was 19 months; range, 8–42 months). Effectiveness and safety were assessed from changes in Central Retinal Thickness (measured using spectral domain optical coherence tomography), corrected distance visual acuity, uveitic activity, and intraocular pressure. The main outcome measures were changes in Central Retinal Thickness, corrected distance visual acuity, uveitic activity, and intraocular pressure. In 11/11 eyes, Central Retinal Thickness improved between months 1 and 3. The mean maximum decrease of Central Retinal Thickness throughout the follow-up period was 168 ± 202 μm (± standard deviation). Nine out of 11 eyes showed an improvement in corrected distance visual acuity (between + 1 and + 8 lines), and 2/11 eyes lost corrected distance visual acuity (− 1 and − 3 lines, respectively). Nine out of 11 eyes presented with inactive inflammation during the follow-up period, and in 1/11 eyes, there was a relapse at month 42. Four out of 11 eyes presented with a relapse of macular edema between months 3 and 8. The mean increase in intraocular pressure was 2.1 ± 4.7 mmHg. Nine eyes were pseudophakic prior to implantation of the injectable fluocinolone acetonide intravitreal implant. Both phakic patients developed a cataract that was treated with cataract surgery in the follow-up period. Conclusions In this small case series with long-term follow-up, treatment of non-infectious uveitic macular edema with the injectable fluocinolone acetonide implant was associated with improved Central Retinal Thickness and corrected distance visual acuity and a manageable safety profile. The advantage of this device is the long-term drug release and the fact that it can be injected into the vitreous as a minor surgical procedure, which is in contrast to other treatment options.

  • Injectable 0.19-mg fluocinolone acetonide intravitreal implant for the treatment of non-infectious uveitic macular edema.
    Journal of ophthalmic inflammation and infection, 2019
    Co-Authors: Lea F. Weber, Stefanie Marx, Gerd U. Auffarth, Alexander F. Scheuerle, Tamer Tandogan, Christian Mayer, Ramin Khoramnia
    Abstract:

    A retrospective observational clinical study to evaluate the safety and effectiveness of the injectable 0.19-mg fluocinolone acetonide intravitreal implant (ILUVIEN) in the treatment of non-infectious uveitic macular edema. Data are presented from eight patients (11 eyes) with non-infectious uveitic macular edema who were treated with a 0.19-mg fluocinolone acetonide implant. Nine out of 11 eyes were pseudophakic prior to implantation of fluocinolone acetonide implant, and both phakic eyes required cataract surgery during the follow-up period (the median follow-up was 19 months; range, 8–42 months). Effectiveness and safety were assessed from changes in Central Retinal Thickness (measured using spectral domain optical coherence tomography), corrected distance visual acuity, uveitic activity, and intraocular pressure. The main outcome measures were changes in Central Retinal Thickness, corrected distance visual acuity, uveitic activity, and intraocular pressure. In 11/11 eyes, Central Retinal Thickness improved between months 1 and 3. The mean maximum decrease of Central Retinal Thickness throughout the follow-up period was 168 ± 202 μm (± standard deviation). Nine out of 11 eyes showed an improvement in corrected distance visual acuity (between + 1 and + 8 lines), and 2/11 eyes lost corrected distance visual acuity (− 1 and − 3 lines, respectively). Nine out of 11 eyes presented with inactive inflammation during the follow-up period, and in 1/11 eyes, there was a relapse at month 42. Four out of 11 eyes presented with a relapse of macular edema between months 3 and 8. The mean increase in intraocular pressure was 2.1 ± 4.7 mmHg. Nine eyes were pseudophakic prior to implantation of the injectable fluocinolone acetonide intravitreal implant. Both phakic patients developed a cataract that was treated with cataract surgery in the follow-up period. In this small case series with long-term follow-up, treatment of non-infectious uveitic macular edema with the injectable fluocinolone acetonide implant was associated with improved Central Retinal Thickness and corrected distance visual acuity and a manageable safety profile. The advantage of this device is the long-term drug release and the fact that it can be injected into the vitreous as a minor surgical procedure, which is in contrast to other treatment options.